# REGADENOSON
> **ANDA207604** · Abbreviated New Drug Application (Generic) · Sponsor: APOTEX · Approved 2022-04-11
## Drug
- **FDA Application Number:** ANDA207604
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** REGADENOSON
- **Generic name:** REGADENOSON
- **Active ingredients:** REGADENOSON
- **Dosage form:** SOLUTION
- **Route:** INTRAVENOUS
- **Marketing status:** Prescription
- **Sponsor:** APOTEX
- **Manufacturer:** Apotex Corp.
- **First approval:** 2022-04-11
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207604)
---
*MORVS · CC0 1.0*